Latest California Healthline Stories
Misinformation Clouds America’s Most Popular Emergency Contraception
At a moment when half of U.S. states stand poised to outlaw or sharply curtail abortion services, the nation’s most popular emergency contraception brand rests in the unlikely stewardship of two private equity firms.
Skirmishes Over Medication Abortion Renews Debate on State vs. Federal Powers
The Biden administration may have authority to allow the use of abortion pills even in states where the practice could be outlawed, say legal experts.
KHN’s ‘What the Health?’: A(nother) Very Sad Week
Two mass shootings in two weeks — one at a Texas elementary school that killed 19 fourth graders and two teachers — have reignited the “guns-as-public-health-problem” debate. But political consensus seems as far away as ever. Meanwhile, the FDA is in the congressional hot seat over its handling of the infant formula shortage. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg News, and Rachana Pradhan of KHN join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Richard Baron, head of the American Board of Internal Medicine, about how doctors should discipline colleagues who spread medical misinformation.
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
After years of failure, the Maryland company aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market?
High-Tech’s Business Model Hasn’t Worked for the Cue Covid Test
Cue got attention with a Super Bowl ad for a stylish high-tech covid-testing machine to use at home. But the product is expensive, which has limited the San Diego company’s market.
As Red Cross Moves to Pricey Blood Treatment Method, Hospitals Call for More Choice
The nation’s largest supplier of platelets is moving to a method it says is easier for hospitals, but one that sharply raises costs, leading some centers to demand more options.
Should You Worry About Data From Your Period-Tracking App Being Used Against You?
After a leaked Supreme Court draft opinion was published May 2 suggesting that Roe v. Wade would soon be overturned, social media users started worrying that their use of period-tracking apps could lead to trouble if they sought an abortion and lived in a state with strict limits or bans on the procedure.
KHN’s ‘What the Health?’: The Invisible Pandemic
Covid cases are again climbing, but you wouldn’t know it from the behavior of public health and elected officials, much less the general public, all of whom seem to want to put the pandemic in the rearview mirror. Meanwhile, the fallout over the leaked Supreme Court draft opinion on abortion continues even as the Senate fails — again — to muster the votes to write abortion rights into law. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Alice Miranda Ollstein of Politico, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
KHN’s ‘What the Health?’: Leaked Abortion Opinion Rocks Washington’s World
The unprecedented early leak of a Supreme Court draft opinion that would overturn the landmark abortion-rights ruling Roe v. Wade has heated the national abortion debate to boiling. Meanwhile, the FDA, after years of consideration, moves to ban menthol flavors in cigarettes and cigars. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Shefali Luthra of the 19th, and Jessie Hellmann of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Paula Andalo, who wrote the latest KHN-NPR “Bill of the Month” episode about a family whose medical debt drove them to seek care south of the border.
Why Cheap, Older Drugs That Might Treat Covid Never Get Out of the Lab
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.